Insmed Inc
NASDAQ:INSM

Watchlist Manager
Insmed Inc Logo
Insmed Inc
NASDAQ:INSM
Watchlist
Price: 70.2 USD -1.22% Market Closed
Market Cap: 12.8B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one INSM stock under the Base Case scenario is 87.39 USD. Compared to the current market price of 70.2 USD, Insmed Inc is Undervalued by 20%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

INSM Relative Value
Base Case
87.39 USD
Undervaluation 20%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

34.6
P/S
P/S
Price to Sales
34.6
vs History
12
vs Industry
23
Median 3Y
13
Median 5Y
15.5
Industry
6.5
Forward
26.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-6
Median 5Y
-7.6
Industry
22
Forward
-12.9
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-7.5
Median 5Y
-8.9
Industry
18.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-18.2
Median 5Y
-16.3
Industry
23.4
More Details
44.1
P/B
P/B
Price to Book Value
44.1
vs History
14
vs Industry
1
Median 3Y
17.8
Median 5Y
8.5
Industry
2.2
More Details
33.8
EV/S
EV/S
Enterprise Value to Sales
33.8
vs History
11
vs Industry
19
Median 3Y
14.2
Median 5Y
15.3
Industry
7.1
Forward
26
More Details
44.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
44.2
vs History
11
vs Industry
15
Median 3Y
18.1
Median 5Y
19.4
Industry
8.7
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-7.1
Median 5Y
-8.6
Industry
3.3
Forward
-13.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-6.9
Median 5Y
-8.2
Industry
3.1
Forward
-12.6
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-7.9
Median 5Y
-8.6
Industry
4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-7.6
Median 5Y
-8.4
Industry
2.6
More Details
23.9
EV/IC
EV/IC
Enterprise Value to IC
23.9
vs History
11
vs Industry
9
Median 3Y
8.1
Median 5Y
8.9
Industry
4.3
More Details

Multiples Across Competitors

INSM Competitors Multiples
Insmed Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Insmed Inc
NASDAQ:INSM
12.6B USD 34.6 -13.8 -15.9 -15.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 837 576.7 -165 577.8 -201 064.3 -198 769.9
US
Abbvie Inc
NYSE:ABBV
303.1B USD 5.4 71.5 14.4 21.7
US
Amgen Inc
NASDAQ:AMGN
151.7B USD 4.5 37.1 15.3 27
US
Gilead Sciences Inc
NASDAQ:GILD
130.7B USD 4.5 272.3 10.7 13.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.8B USD 11.3 -233.1 25.5 26.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 022.2 -516 -561.9 -546.9
AU
CSL Ltd
ASX:CSL
116.3B AUD 4.9 27 16.7 20.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.2B USD 4.2 13.6 8.2 9.1
US
Seagen Inc
F:SGT
39.3B EUR 19.5 -59.7 -64.3 -58.1
NL
argenx SE
XBRU:ARGX
31.3B EUR 16.3 42.8 315.6 -2 324.9
P/S Multiple
Revenue Growth P/S to Growth
US
Insmed Inc
NASDAQ:INSM
Average P/S: 3 167 245.8
34.6
73%
0.5
FR
Pharnext SCA
OTC:PNEXF
34 837 576.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.4
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.3
10%
1.1
US
E
Epizyme Inc
F:EPE
2 022.2
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
7%
0.6
US
S
Seagen Inc
F:SGT
19.5
30%
0.6
NL
argenx SE
XBRU:ARGX
16.3
37%
0.4
P/E Multiple
Earnings Growth PEG
US
Insmed Inc
NASDAQ:INSM
Average P/E: 77.4
Negative Multiple: -13.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 577.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
71.5
87%
0.8
US
Amgen Inc
NASDAQ:AMGN
37.1
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
272.3
187%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -233.1 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516 N/A N/A
AU
CSL Ltd
ASX:CSL
27
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
12%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.7 N/A N/A
NL
argenx SE
XBRU:ARGX
42.8
26%
1.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Insmed Inc
NASDAQ:INSM
Average EV/EBITDA: 58
Negative Multiple: -15.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 064.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.4
14%
1
US
Amgen Inc
NASDAQ:AMGN
15.3
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.7
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
18%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.9 N/A N/A
AU
CSL Ltd
ASX:CSL
16.7
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
8.2
14%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.3 N/A N/A
NL
argenx SE
XBRU:ARGX
315.6
166%
1.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Insmed Inc
NASDAQ:INSM
Average EV/EBIT: 19.8
Negative Multiple: -15.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 769.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
21.7
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
27
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.4
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -546.9 N/A N/A
AU
CSL Ltd
ASX:CSL
20.9
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.1
17%
0.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 324.9 N/A N/A

See Also

Summary
INSM intrinsic value, competitors valuation, and company profile.
DCF Valuation
INSM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
INSM stock valuation using valuation multiples.
Wall Street Estimates
INSM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
INSM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 247,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.